Pre-Open Stock Movers 01/03: (OHRP) (CELG) (DBVT) Higher; (AAPL) (LITE) (BMY) Lower (more...)

January 3, 2019 9:22 AM

Pre-Open Movers

Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) 73.6% HIGHER; announced today that it has entered into a definitive merger agreement with NeuBase Therapeutics, Inc., under which the stockholders of NeuBase would become the majority holders of the combined company. The proposed merger will create a public company focused on advancing NeuBases peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL) technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations.

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) 70.4% LOWER; announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 400 mg BID) in children aged 6 17 with Attention Deficit Hyperactivity Disorder (ADHD) with an mGluR copy number variant (Part A) or without an mGluR copy number variant (Part B), did not achieve statistical significance on the primary endpoint of reduction of ADHD-RS in either Part A or Part B after 6 weeks of treatment with AEVI-001. AEVI-001 was safe and well tolerated. Reported adverse events were minimal and similar across both Part A and Part B treatment groups.

Kitov Pharma (NASDAQ: KTOV) 44% HIGHER; announced it has signed an exclusive marketing and distribution agreement with Coeptis Pharmaceuticals for the U.S. market. Coeptis will commercialize Kitov’s combination drug, Consensi™, intended to simultaneously treat osteoarthritis pain and hypertension.

Celgene Corporation (NASDAQ: CELG) 34% HIGHER; Bristol-Myers Squibb Company (NYSE: BMY) and Celgene Corporation (NASDAQ: CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share and $50.00 in cash for each share of Celgene. Celgene shareholders will also receive one tradeable Contingent Value Right (CVR) for each share of Celgene, which will entitle the holder to receive a payment for the achievement of future regulatory milestones. The Boards of Directors of both companies have approved the combination.

Alliqua Biomedical (NASDAQ: ALQA) 29.7% HIGHER; CEO Provides Update to Shareholders

BioXcel Therapeutics, Inc. (NASDAQ: BTAI) 24% HIGHER; announced proof-of-concept data from its Phase 1 study of IV (intravenous) dexmedetomidine (Dex) for acute treatment of agitation in patients with Senile Dementia of the Alzheimers Type (SDAT). The positive data from this Phase 1 trial provides evidence to support the continued clinical development of BXCL501 for the acute treatment of agitation under the accelerated Fast Track regulatory process. Agitation is common across all severities of Alzheimers Disease, with an increasing prevalence as the disease progresses1. BTI is a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology.

Cocrystal Pharma, Inc. (NASDAQ: COCP) 23.8% HIGHER; entered into an exclusive license and collaboration agreement with Merck (NYSE: MRK) to discover and develop certain proprietary influenza A/B antiviral agents.

DBV Technologies (Nasdaq: DBVT) 15.9% HIGHER; announced the following changes to its leadership team as the Company strengthens its organizational competencies in the development of the Viaskin platform

Apple (NASDAQ: AAPL) 9.2% LOWER; warns for Q1. Sees revenue of approximately $84 billion, versus the consensus of $91.49 billion.

Lumentum Holdings Inc. (NASDAQ: LITE) 8.4% LOWER; Apple suppliers weak following revenue warning.

Bristol-Myers Squibb Company (NYSE: BMY) 8.3% LOWER; Bristol-Myers and Celgene Corporation (NASDAQ: CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share and $50.00 in cash for each share of Celgene. Celgene shareholders will also receive one tradeable Contingent Value Right (CVR) for each share of Celgene, which will entitle the holder to receive a payment for the achievement of future regulatory milestones. The Boards of Directors of both companies have approved the combination.

Skyworks Solutions (NASDAQ: SWKS) 5.8% LOWER; Apple suppliers weak following revenue warning

Moleculin Biotech, Inc., (Nasdaq: MBRX) 5.4% HIGHER; announced that in preliminary animal studies, a second of its lead drugs, WP1732, has demonstrated enhanced activity in combination with checkpoint blockade antibodies in pancreatic cancer.

Broadcom (NASDAQ: AVGO) 4.2% LOWER; Apple suppliers weak following revenue warning.

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) 3.3% HIGHER; In a 13G filing on Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), Steven Cohen's Point72 Asset Management, L.P. disclosed a 5.7%, or 4,781,895 share, stake in the company

Netflix (NASDAQ: NFLX) 2.9% LOWER; FAANGs down on Apple warning

Teva Pharma (NYSE: TEVA) 2.7% HIGHER; BofAMerrill Lynchh upgraded from Underperform to Buy with a price target of $20.00.

Amazon.com (NASDAQ: AMZN) 2.3% LOWER; FAANGs down on Apple warning

Intel (NASDAQ: INTC) 1.7% LOWER; Apple suppliers weak following revenue warning.

Qualcomm (NASDAQ: QCOM) 1.7% LOWER; Apple suppliers weak following revenue warning.

Facebook (NASDAQ: FB) 1.7% LOWER; FAANGs down on Apple warning

Categories

Special Reports

Next Articles